Clinical Trials Browser

Phase 1 × talquetamab × 30 days × Clear all

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT06348108 2026-03-13

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT03399799 2026-03-12

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms